CDRD-UBC spin-off Sitka Biopharma seeded by Quark Venture

Sitka Biopharma, a biotechnology spin-off of the Centre for Drug Research and Development (CDRD) and the University of British Columbia (UBC), recently raised seed funding. The investment, the value of which was not disclosed, came from life sciences venture capital firm Quark Venture. Founded in 2013, Vancouver-based Sitka is a developer of nanoparticle platform technology aimed at increasing drug absorption in difficult-to-penetrate tissues. The seed funding will allow the company to advance its lead compound for the treatment of bladder cancer into clinical trials.

CanadaNorth AmericaBriefs